{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:40:38Z","timestamp":1792665638462,"version":"4.5.0"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.critrevonc.2026.105642","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:14:51Z","timestamp":1791846891000},"page":"105642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rewiring the tumor\u2013immune ecosystem: Extracellular vesicles in the next era of cancer immunotherapy"],"prefix":"10.1016","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8719-4738","authenticated-orcid":false,"given":"Ahmed Reda","family":"Bahr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Basem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel Rahman","family":"Alaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Basem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0634-652X","authenticated-orcid":false,"given":"Mariam Hossam","family":"El-deen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9981-0622","authenticated-orcid":false,"given":"Esraa M.","family":"Halawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105642_bib1","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12964-024-01995-y","article-title":"MDSC: a new potential breakthrough in CAR-T therapy for solid tumors","volume":"22","author":"Abdalsalam","year":"2024","journal-title":"Cell. Commun. Signal."},{"key":"10.1016\/j.critrevonc.2026.105642_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101246","article-title":"Disseminating transformative gene and cell therapy research","volume":"32","author":"Abou-el-Enein","year":"2024","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"10.1016\/j.critrevonc.2026.105642_bib3","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/s41467-025-56527-0","article-title":"Unlocking the potential of engineered immune cell therapy for solid tumors","volume":"16","author":"Albarr\u00e1n-Fern\u00e1ndez","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105642_bib4","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/s41467-025-56527-0","article-title":"Unlocking the potential of engineered immune cell therapy for solid tumors","volume":"16","author":"Albarr\u00e1n-Fern\u00e1ndez","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105642_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib6","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 Enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105642_bib7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12672-025-04276-3","article-title":"Engineering CAR T NK and NKT cell therapies to target cancer stem cells and overcome stem like resistance","volume":"17","author":"Allela","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib8","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41698-025-01170-7","article-title":"CAR-macrophages in solid tumors: promise, progress, and prospects","volume":"9","author":"Alrehaili","year":"2025","journal-title":"Npj Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib9","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3389\/fphar.2025.1614325","article-title":"Engineered immune cell therapies for solid tumors: pharmacological advances, clinical outcomes, and future directions","volume":"16","author":"Althafar","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib10","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1038\/s41467-024-47799-z","article-title":"CAR affinity modulates the sensitivity of CAR-T cells to PD-1\/PD-L1-mediated inhibition","volume":"15","author":"Andreu-Saumell","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105642_bib11","series-title":"Cell-Secreted Vesicles, Methods in Molecular Biology","first-page":"69","article-title":"Methodologies for Scalable Production of High-Quality Purified Small Extracellular Vesicles from Conditioned Medium","author":"Andriolo","year":"2023"},{"key":"10.1016\/j.critrevonc.2026.105642_bib12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3390\/cells13040337","article-title":"Extracellular vesicles, circulating tumor cells, and immune checkpoint inhibitors: hints and promises","volume":"13","author":"Bandini","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105642_bib13","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/cancers17020282","article-title":"Comprehensive review of early and late toxicities in CAR T-cell therapy and bispecific antibody treatments for hematologic malignancies","volume":"17","author":"Bangolo","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105642_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: State of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2026.105642_bib15","doi-asserted-by":"crossref","first-page":"8047","DOI":"10.1038\/s41467-023-43914-8","article-title":"Metabolic tagging of extracellular vesicles and development of enhanced extracellular vesicle based cancer vaccines","volume":"14","author":"Bhatta","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105642_bib16","doi-asserted-by":"crossref","first-page":"597","DOI":"10.20517\/evcna.2024.34","article-title":"Choice of size-exclusion chromatography column affects recovery, purity, and miRNA cargo analysis of extracellular vesicles from human plasma","volume":"5","author":"Bracht","year":"2024","journal-title":"Extracell. Vesicles Circ. Nucleic Acids"},{"key":"10.1016\/j.critrevonc.2026.105642_bib17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","article-title":"Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations","volume":"24","author":"Butterfield","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.70068","article-title":"Dendritic cell derived-extracellular vesicles engineered to express interleukin-12 and anti-CTLA-4 on their surface for combinational cancer immunotherapy","volume":"14","author":"Chen","year":"2025","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.critrevonc.2026.105642_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1315283","article-title":"TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells","volume":"15","author":"Cianciotti","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113620","article-title":"Engineered dendritic cells-derived extracellular vesicles for cancer immunotherapy","volume":"381","author":"Coelho","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2026.105642_bib21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-025-01739-6","article-title":"Combination immunotherapy in hepatocellular carcinoma: synergies among immune checkpoints, TKIs, and chemotherapy","volume":"18","author":"Dai","year":"2025","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib22","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1007\/s00432-022-04440-0","article-title":"Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy","volume":"149","author":"Davern","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13046-022-02379-1","article-title":"Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer","volume":"41","author":"De Miguel-Perez","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105642_bib24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13046-024-02997-x","article-title":"Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC","volume":"43","author":"De Miguel\u2011Perez","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105642_bib25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.critrevonc.2026.105642_bib26","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.3390\/biomedicines13102497","article-title":"Dendritic cell-derived exosomes: next generation of cancer immunotherapy","volume":"13","author":"Dhar","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2026.105642_bib27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/cei\/uxac006","article-title":"Extracellular vesicles containing PD-L1 contribute to CD8+ T-cell immune suppression and predict poor outcomes in small cell lung cancer","volume":"207","author":"Dou","year":"2022","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib28","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12951-023-01973-5","article-title":"Extracellular vesicles: a rising star for therapeutics and drug delivery","volume":"21","author":"Du","year":"2023","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.critrevonc.2026.105642_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008155","article-title":"CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation","volume":"12","author":"Eitler","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105642_bib30","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1038\/s41388-023-02826-z","article-title":"Translation of AI into oncology clinical practice","volume":"42","author":"El Naqa","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105642_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1735763","article-title":"CAR-\u03b3\u03b4 T cells: a new paradigm of programmable innate immune sentinels and their systemic applications in cancer and beyond","volume":"16","author":"Fang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib32","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.3390\/jcm13216537","article-title":"Next-generation immunotherapy: advancing clinical applications in cancer treatment","volume":"13","author":"Garg","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.critrevonc.2026.105642_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216168","article-title":"Dendritic cell-derived exosomes: a new horizon in personalized cancer immunotherapy?","volume":"562","author":"Ghorbaninezhad","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105642_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ads4214","article-title":"Target antigen\u2013displaying extracellular vesicles boost CAR T cell efficacy in cell and mouse models of neuroblastoma","volume":"17","author":"Giudice","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105642_bib35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.reth.2025.03.006","article-title":"MSC-derived extracellular vesicles: Precision miRNA delivery for overcoming cancer therapy resistance","volume":"29","author":"Goyal","year":"2025","journal-title":"Regen. Ther."},{"key":"10.1016\/j.critrevonc.2026.105642_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114974","article-title":"Towards artificial intelligence-enabled extracellular vesicle precision drug delivery","volume":"199","author":"Greenberg","year":"2023","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.critrevonc.2026.105642_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1021270","article-title":"Exosomal RNF157 mRNA from prostate cancer cells contributes to M2 macrophage polarization through destabilizing HDAC1","volume":"12","author":"Guan","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.149918","article-title":"A novel MICA\/B-targeted chimeric antigen receptor augments the cytotoxicity of NK cells against tumor cells","volume":"710","author":"Guo","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105642_bib39","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s12951-024-02719-7","article-title":"Acidity-activatable dynamic hybrid nanoplatforms derived from extracellular vesicles of M1 macrophages enhance cancer immunotherapy through synergistic triple immunotherapy","volume":"22","author":"Guo","year":"2024","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.critrevonc.2026.105642_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113961","article-title":"Dosing extracellular vesicles","volume":"178","author":"Gupta","year":"2021","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.critrevonc.2026.105642_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112820","article-title":"Extracellular vesicles reshape the tumor microenvironment to improve cancer immunotherapy: current knowledge and future prospects","volume":"140","author":"Hang","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216960","article-title":"Revisiting the advances and challenges in the clinical applications of extracellular vesicles in cancer","volume":"593","author":"He","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105642_bib43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41392-024-01891-4","article-title":"Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies","volume":"9","author":"He","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105642_bib44","doi-asserted-by":"crossref","first-page":"8317","DOI":"10.1039\/D3NR06565K","article-title":"Genetically engineered cell-derived nanovesicles for cancer immunotherapy","volume":"16","author":"He","year":"2024","journal-title":"Nanoscale"},{"key":"10.1016\/j.critrevonc.2026.105642_bib45","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","article-title":"Dendritic cells as orchestrators of anticancer immunity and immunotherapy","volume":"21","author":"Heras-Murillo","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib46","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41565-021-00931-2","article-title":"Extracellular vesicles as a next-generation drug delivery platform","volume":"16","author":"Herrmann","year":"2021","journal-title":"Nat. Nanotechnol."},{"issue":"96\u201396","key":"10.1016\/j.critrevonc.2026.105642_bib47","article-title":"Spatial multi-omics analyses of the tumor immune microenvironment","volume":"29","author":"Hsieh","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.critrevonc.2026.105642_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.70145","article-title":"GMP-compliant process for the manufacturing of an extracellular vesicles-enriched secretome product derived from cardiovascular progenitor cells suitable for a phase i clinical trial","volume":"14","author":"Humbert","year":"2025","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.critrevonc.2026.105642_bib49","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/cells15010021","article-title":"CAR-NK engineering to overcome TME barriers","volume":"15","author":"Islam","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105642_bib50","doi-asserted-by":"crossref","first-page":"902","DOI":"10.3390\/cells11050902","article-title":"Evaluation of immunoregulatory biomarkers on plasma small extracellular vesicles for disease progression and early therapeutic response in head and neck cancer","volume":"11","author":"Jablonska","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105642_bib51","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13045-025-01688-0","article-title":"Cancer associated fibroblasts in cancer development and therapy","volume":"18","author":"Jia","year":"2025","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib52","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.3390\/cancers15102838","article-title":"Surface-engineered extracellular vesicles in cancer immunotherapy","volume":"15","author":"Johnson","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105642_bib53","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jconrel.2024.10.025","article-title":"Enhancing preventive and therapeutic cancer vaccine efficacy through biotherapeutic ligand-associated extracellular vesicles","volume":"376","author":"Kahraman","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2026.105642_bib54","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.cell.2023.03.010","article-title":"The role of extracellular vesicles in cancer","volume":"186","author":"Kalluri","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105642_bib55","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.3390\/cancers15102721","article-title":"Recent advances in molecular mechanisms of cancer immunotherapy","volume":"15","author":"Kciuk","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105642_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/biomethods\/bpae032","article-title":"High-throughput surface epitope immunoaffinity isolation of extracellular vesicles and downstream analysis","volume":"9","author":"Khanabdali","year":"2024","journal-title":"Biol. Methods Protoc."},{"key":"10.1016\/j.critrevonc.2026.105642_bib57","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s12276-024-01201-6","article-title":"Recent advances in extracellular vesicles for therapeutic cargo delivery","volume":"56","author":"Kim","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.critrevonc.2026.105642_bib58","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/14712598.2024.2399141","article-title":"Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors","volume":"24","author":"Klampatsa","year":"2024","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105642_bib59","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/14712598.2024.2399141","article-title":"Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors","volume":"24","author":"Klampatsa","year":"2024","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105642_bib60","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccell.2024.01.002","article-title":"Inosine induces stemness features in CAR-T cells and enhances potency","volume":"42","author":"Klysz","year":"2024","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105642_bib61","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41571-024-00870-6","article-title":"Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine","volume":"21","author":"Kumagai","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41392-024-01735-1","article-title":"Extracellular vesicles as tools and targets in therapy for diseases","volume":"9","author":"Kumar","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105642_bib63","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41392-024-01735-1","article-title":"Extracellular vesicles as tools and targets in therapy for diseases","volume":"9","author":"Kumar","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105642_bib64","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105642_bib65","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105642_bib66","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/bloodadvances.2022007423","article-title":"Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells","volume":"7","author":"Lamble","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105642_bib67","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1182\/bloodadvances.2024014860","article-title":"CD19.CAR T-cell\u2013derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy","volume":"9","author":"Lanuti","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105642_bib68","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.7150\/thno.68864","article-title":"Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1","volume":"12","author":"Lee","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.critrevonc.2026.105642_bib69","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2024.2315655","article-title":"Immunotherapy resistance in solid tumors: mechanisms and potential solutions","volume":"25","author":"Lefler","year":"2024","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105642_bib70","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012321","article-title":"Envirotune-CAR-T: a hypoxia-responsive and glutamine-enhanced CAR-T cell therapy for overcoming tumor microenvironment-mediated suppression","volume":"13","author":"Li","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105642_bib71","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-025-02367-9","article-title":"Transforming acidic coiled-coil-containing protein 3-mediated lipid metabolism reprogramming impairs CD8+ T-cell cytotoxicity in hepatocellular carcinoma","volume":"10","author":"Li","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105642_bib72","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12929-024-00998-8","article-title":"Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies","volume":"31","author":"Li","year":"2024","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.critrevonc.2026.105642_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202370416","article-title":"Engineered extracellular vesicles to enhance antigen presentation for boosting light-driven tumor immunotherapy","volume":"19","author":"Li","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.critrevonc.2026.105642_bib74","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41746-024-01043-6","article-title":"Informing immunotherapy with multi-omics driven machine learning","volume":"7","author":"Li","year":"2024","journal-title":"Npj Digit. Med."},{"key":"10.1016\/j.critrevonc.2026.105642_bib75","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.70332","article-title":"Regulatory challenges and opportunities for cell-derived extracellular vesicles in pharmaceutical development: a european and global perspective","volume":"15","author":"Limongi","year":"2026","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.critrevonc.2026.105642_bib76","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41571-025-01000-6","article-title":"Enhancing immunotherapy with tumour-responsive nanomaterials","volume":"22","author":"Linderman","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib77","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/s41419-024-07191-7","article-title":"PD-L2 of tumor-derived exosomes mediates the immune escape of cancer cells via the impaired T cell function","volume":"15","author":"Liu","year":"2024","journal-title":"Cell. Death Dis."},{"issue":"272-287","key":"10.1016\/j.critrevonc.2026.105642_bib78","article-title":"Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105642_bib79","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s12951-025-03321-1","article-title":"Macrophage-derived exosomes in cancer: a double-edged sword with therapeutic potential","volume":"23","author":"Liu","year":"2025","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.critrevonc.2026.105642_bib80","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/cells13020146","article-title":"Allogeneic CAR-T therapy technologies: has the promise been met?","volume":"13","author":"Lonez","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105642_bib81","doi-asserted-by":"crossref","first-page":"517","DOI":"10.20517\/evcna.2025.35","article-title":"Harnessing artificial intelligence for engineering extracellular vesicles","volume":"6","author":"Lu","year":"2025","journal-title":"Extracell. Vesicles Circ. Nucleic Acids"},{"key":"10.1016\/j.critrevonc.2026.105642_bib82","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12294","article-title":"TGF\u03b2+ small extracellular vesicles from head and neck squamous cell carcinoma cells reprogram macrophages towards a pro-angiogenic phenotype","volume":"11","author":"Ludwig","year":"2022","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.critrevonc.2026.105642_bib83","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jconrel.2024.08.017","article-title":"Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunity","volume":"374","author":"Luo","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2026.105642_bib84","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adm7269","article-title":"Tumor extracellular vesicle\u2013derived PD-L1 promotes T cell senescence through lipid metabolism reprogramming","volume":"17","author":"Ma","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105642_bib85","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105642_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.749753","article-title":"Competitive endogenous role of the LINC00511\/miR-185-3p axis and miR-301a-3p from liquid biopsy as molecular markers for breast cancer diagnosis","volume":"11","author":"Mahmoud","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1785587","article-title":"From immune exclusion to exhaustion: tumor microenvironment drives therapy response","volume":"17","author":"Maletin","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib88","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jconrel.2024.10.057","article-title":"Extracellular vesicles powered cancer immunotherapy: Targeted delivery of adenovirus-based cancer vaccine in humanized melanoma model","volume":"376","author":"Mathlouthi","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2026.105642_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101073","article-title":"Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting","volume":"60","author":"Merino","year":"2023","journal-title":"Blood Rev."},{"key":"10.1016\/j.critrevonc.2026.105642_bib90","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1038\/s41409-021-01420-9","article-title":"Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors","volume":"56","author":"Mohty","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2026.105642_bib91","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3324\/haematol.2022.281456","article-title":"Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3- mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia","volume":"108","author":"Niswander","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2026.105642_bib92","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1182\/bloodadvances.2022008272","article-title":"Engineering amino acid uptake or catabolism promotes CAR T-cell adaption to the tumor environment","volume":"7","author":"Panetti","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105642_bib93","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq3016","article-title":"Metabolic challenges and interventions in CAR T cell therapy","volume":"8","author":"Peng","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib94","doi-asserted-by":"crossref","first-page":"5618","DOI":"10.1038\/s41467-024-49678-z","article-title":"Enhancing extracellular vesicle cargo loading and functional delivery by engineering protein-lipid interactions","volume":"15","author":"Peruzzi","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105642_bib95","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41416-021-01668-4","article-title":"Utilising extracellular vesicles for early cancer diagnostics: benefits, challenges and recommendations for the future","volume":"126","author":"Pink","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105642_bib96","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/0008-5472.CAN-23-2042","article-title":"Targeting tumor heterogeneity with neoantigen-based cancer vaccines","volume":"84","author":"Pounraj","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105642_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2026.1683726","article-title":"Combination of oncolytic viruses and immune checkpoint inhibitors for treatment of high-grade gliomas","volume":"17","author":"Qian","year":"2026","journal-title":"Front. Neurol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2023.102709","article-title":"Antigen density quantification of cell-surface immunotherapy targets by flow cytometry: multi-antigen assay of neuroblastoma bone marrow metastasis","volume":"4","author":"Radosevich","year":"2023","journal-title":"STAR Protoc."},{"key":"10.1016\/j.critrevonc.2026.105642_bib99","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","article-title":"Clinical pharmacology of cytokine release syndrome with T-cell\u2013engaging bispecific antibodies: current insights and drug development strategies","volume":"31","author":"Radtke","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105642_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1586892","article-title":"Dendritic cell-derived exosomes as anti-cancer cell-free agents: new insights into enhancing immunogenic effects","volume":"16","author":"Redkin","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2024.1476737","article-title":"Extracellular vesicles for cancer therapy: potential, progress, and clinical challenges","volume":"12","author":"Ren","year":"2024","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib102","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","article-title":"Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies","volume":"22","author":"Ruella","year":"2023","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.critrevonc.2026.105642_bib103","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2093426","article-title":"Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality","volume":"11","author":"Schoutrop","year":"2022","journal-title":"OncoImmunology"},{"key":"10.1016\/j.critrevonc.2026.105642_bib104","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3390\/cells13090754","article-title":"Extracellular vesicles in pathophysiology: a prudent target that requires careful consideration","volume":"13","author":"Shahi","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105642_bib105","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40164-024-00504-8","article-title":"Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy","volume":"13","author":"Shao","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib106","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s10238-025-01751-7","article-title":"Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective","volume":"25","author":"Sherafat","year":"2025","journal-title":"Clin. Exp. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105642_bib107","doi-asserted-by":"crossref","first-page":"6533","DOI":"10.3390\/ijms25126533","article-title":"Extracellular Vesicles as Next-Generation Diagnostics and Advanced Therapy Medicinal Products","volume":"25","author":"Stawarska","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105642_bib108","doi-asserted-by":"crossref","DOI":"10.1002\/inmd.70084","article-title":"Extracellular vesicle-based vaccines and immunotherapeutics for treatment of cancer","volume":"4","author":"Tan","year":"2026","journal-title":"Interdiscip. Med."},{"key":"10.1016\/j.critrevonc.2026.105642_bib109","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202303835","article-title":"Extracellular vesicles-derived hybrid nanoplatforms for amplified CD47 blockade-based cancer immunotherapy","volume":"35","author":"Tang","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.critrevonc.2026.105642_bib110","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-62783-9","article-title":"Improved recovery of urinary small extracellular vesicles by differential ultracentrifugation","volume":"14","author":"Teixeira-Marques","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105642_bib111","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1021\/acsnano.1c05505","article-title":"Immune checkpoint inhibition in GBM primed with radiation by engineered extracellular vesicles","volume":"16","author":"Tian","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.critrevonc.2026.105642_bib112","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7616696","article-title":"Exosomal CXCL14 contributes to M2 macrophage polarization through NF- \u03ba B signaling in prostate cancer","volume":"2022","author":"Tian","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.critrevonc.2026.105642_bib113","article-title":"Extracellular vesicles hybrid plasmid-loaded lipid nanovesicles for synergistic cancer immunotherapy","volume":"23","author":"Tong","year":"2023","journal-title":"Mater. Today Biol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib114","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.semcancer.2022.12.008","article-title":"Status quo of extracellular vesicle isolation and detection methods for clinical utility","volume":"88","author":"Visan","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib115","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41419-025-07454-x","article-title":"CAR-T therapy dilemma and innovative design strategies for next generation","volume":"16","author":"Wang","year":"2025","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105642_bib116","article-title":"Tumor-derived extracellular vesicles modulate innate immune responses to affect tumor progression","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105642_bib117","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12404","article-title":"Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches","volume":"13","author":"Welsh","year":"2024","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.critrevonc.2026.105642_bib118","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.3390\/ijms26104835","article-title":"Extracellular vesicle-based drug delivery systems in cancer therapy","volume":"26","author":"Wu","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105642_bib119","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41392-025-02343-3","article-title":"Oncolytic viruses: advanced strategies in cancer therapy","volume":"11","author":"Xiao","year":"2026","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105642_bib120","doi-asserted-by":"crossref","DOI":"10.20517\/cdr.2024.152","article-title":"Cancer-associated fibroblast-derived extracellular vesicles: regulators and therapeutic targets in the tumor microenvironment","author":"Xie","year":"2025","journal-title":"Cancer Drug. Resist."},{"key":"10.1016\/j.critrevonc.2026.105642_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.156035","article-title":"Integrating multi-omics data with artificial intelligence to decipher the role of tumor-infiltrating lymphocytes in tumor immunotherapy","volume":"271","author":"Xie","year":"2025","journal-title":"Pathol. - Res. Pract."},{"key":"10.1016\/j.critrevonc.2026.105642_bib122","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12243","article-title":"Neoantigen-based cancer vaccination using chimeric RNA-loaded dendritic cell-derived extracellular vesicles","volume":"11","author":"Xiong","year":"2022","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.critrevonc.2026.105642_bib123","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41578-023-00617-2","article-title":"Responsive biomaterials: optimizing control of cancer immunotherapy","volume":"9","author":"Xue","year":"2023","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.critrevonc.2026.105642_bib124","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004400","article-title":"PD-L1 blockade restores CAR T cell activity through IFN-\u03b3-regulation of CD163+ M2 macrophages","volume":"10","author":"Yamaguchi","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105642_bib125","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3390\/cells15131213","article-title":"Engineered extracellular vesicles as programmable immune interfaces: surface and cargo engineering for cancer immunotherapy and tolerance","volume":"15","author":"Yamano","year":"2026","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105642_bib126","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.apsb.2020.04.004","article-title":"The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy","volume":"10","author":"Yang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.critrevonc.2026.105642_bib127","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41423-026-01424-9","article-title":"Adaptive resistance in cancer immunotherapy","volume":"23","author":"Yang","year":"2026","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib128","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/2159-8290.CD-20-1209","article-title":"Development of immunotherapy combination strategies in cancer","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105642_bib129","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1038\/s12276-024-01340-w","article-title":"Influencing immunity: role of extracellular vesicles in tumor immune checkpoint dynamics","volume":"56","author":"Ye","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.critrevonc.2026.105642_bib130","doi-asserted-by":"crossref","DOI":"10.1002\/biot.202400374","article-title":"Optimizing conditions of polyethylene glycol precipitation for exosomes isolation from mscs culture media for regenerative treatment","volume":"19","author":"Yu","year":"2024","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.critrevonc.2026.105642_bib131","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s44276-024-00096-0","article-title":"Small extracellular vesicles as biomarkers of response in recurrent\/metastatic HNSCC patients treated with immunotherapy","volume":"2","author":"Zandberg","year":"2024","journal-title":"BJC Rep."},{"key":"10.1016\/j.critrevonc.2026.105642_bib132","article-title":"Cytokine-engineered chimeric antigen receptor-t cell therapy: how to balance the efficacy and toxicity","volume":"13","author":"Zhang","year":"2026","journal-title":"Adv. Sci."},{"key":"10.1016\/j.critrevonc.2026.105642_bib133","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12943-024-02156-y","article-title":"Regulatory T cells in immune checkpoint blockade antitumor therapy","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105642_bib134","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70283","article-title":"Unlocking apoptotic pathways: overcoming tumor resistance in CAR -T-cell therapy","volume":"13","author":"Zhang","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2026.105642_bib135","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s12032-025-02965-1","article-title":"NK-derived exosomes in anti-tumor strategies","volume":"42","author":"Zhang","year":"2025","journal-title":"Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib136","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s12672-025-01781-3","article-title":"Potential and development of cellular vesicle vaccines in cancer immunotherapy","volume":"16","author":"Zhao","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105642_bib137","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41420-024-02077-1","article-title":"Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions","volume":"10","author":"Zhong","year":"2024","journal-title":"Cell. Death Discov."},{"key":"10.1016\/j.critrevonc.2026.105642_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215668","article-title":"Tumor-derived extracellular vesicles induce invalid cytokine release and exhaustion of CD19 CAR-T Cells","volume":"536","author":"Zhu","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105642_bib139","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/s41423-024-01153-x","article-title":"Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy","volume":"21","author":"Zhu","year":"2024","journal-title":"Cell. Mol. Immunol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:06:39Z","timestamp":1792663599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826005299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":139,"alternative-id":["S1040842826005299"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105642","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rewiring the tumor\u2013immune ecosystem: Extracellular vesicles in the next era of cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105642","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105642"}}